Robotic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is there a benefit?
Robotic CRS/HIPEC holds promise to decrease intraoperative blood loss, blood transfusions, and hospital stay while providing similar immediate postoperative outcomes in select patients. These results should be validated in the setting of a prospective trial and effects on long-term oncologic outcomes should be investigated.
Authors
- Brian K. Sparkman (ORCID: https://orcid.org/0000-0001-9953-5088)
- Devon C. Freudenberger (ORCID: https://orcid.org/0000-0002-9117-0130)
- Vignesh Vudatha (ORCID: https://orcid.org/0000-0002-3624-3771)
- Adam Khader (ORCID: https://orcid.org/0000-0002-9276-132X)
- Jose Trevino (ORCID: https://orcid.org/0000-0003-3149-7761)
- Leopoldo Fernandez (ORCID: https://orcid.org/0009-0008-6943-0427)
Institutions
- Virginia Department of Education (US)
- Virginia Commonwealth University (US)
- Veterans Health Administration (US)
Publication Details
- Journal
- Surgical Endoscopy
- Published
- 2024-10-16
- DOI
- https://doi.org/10.1007/s00464-024-11199-7
- Citations
- 3
- Primary Topic
- Intraperitoneal and Appendiceal Malignancies
- Type
- article
- Field-Weighted Citation Impact
- 1.72
Funders
- National Institutes of Health
- National Cancer Institute